TransMedics Group, Inc. (TMDX) delivered earnings per share (EPS) of 70 cents in the first quarter of 2025, which surged 100% year over year. The figure surpassed the Zacks Consensus Estimate by 141.4%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)TMDX’s Revenues in DetailTransMedics registered revenues of $143.5 million in the first quarter, up 48.2% year over year. The figure surpassed the Zacks Consensus Estimate by 16.2%.Per management, the uptick resulted from the increase i ...

TransMedics's ( TMDX ) Q1 results were extremely strong across the board, which is no surprise for anyone that has been tracking transplant volumes and flight activity. While growth could exhibit volatility from quarter to quarter, and competition will increase in the nearRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be a ...

For the quarter ended March 2025, TransMedics (TMDX) reported revenue of $143.54 million, up 48.2% over the same period last year. EPS came in at $0.70, compared to $0.35 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $123.56 million, representing a surprise of +16.17%. The company delivered an EPS surprise of +141.38%, with the consensus EPS estimate being $0.29.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

TransMedics (TMDX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 141.38%. A quarter ago, it was expected that this medical technology company would post earnings of $0.18 per share when it actually produced earnings of $0.19, delivering a surprise of 5.56%.Over the last four quarter ...

TransMedics Group (TMDX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to TransMedics First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Lane Morgan from the Gilmartin Group for a few introductory comments. Please g ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. (Exact name of registrant as specified in its charter) Massachusetts 83-2181531 (State or other jur ...

Exhibit 99.1 TransMedics Reports First Quarter 2025 Financial Results Andover, Mass. – May 8, 2025 – TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights "Overall, we are very pleased with our first quarter performance, which we believe underscores the unique attributes of our busines ...

ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025.Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024 Generated net income of $25.7 million or $0.70 per fully diluted share in ...

The upcoming report from TransMedics (TMDX) is expected to reveal quarterly earnings of $0.29 per share, indicating a decline of 17.1% compared to the year-ago period. Analysts forecast revenues of $123.56 million, representing an increase of 27.6% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's earnings disclosure, it ...

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased TransMedics securities during the Class Period you may be entitled to compensation without payment of any ...